Eculizumab
Modify Date: 2024-01-11 00:32:08
Eculizumab structure
|
Common Name | Eculizumab | ||
|---|---|---|---|---|
| CAS Number | 219685-50-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EculizumabEculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research[1]. |
| Name | Unii-A3ulp0F556 |
|---|
| Description | Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Eline A Dubois,et al. Eculizumab. Br J Clin Pharmacol. 2009 Sep;68(3):318-9. |
| Storage condition | -20°C |
|---|